ArticleFrontiers in oncology2026
Preoperative prediction of microvascular invasion in hepatocellular carcinoma ≤5 cm based on contrast-enhanced ultrasound features and LI-RADS categorization: a multicenter study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the predictive value of contrast-enhanced ultrasound (CEUS) features combined with Liver Imaging Reporting and Data System (LI-RADS) categorization for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) ≤5 cm. Methods: This multicenter retrospective study enrolled adult patients with HCC ≤5 cm who underwent CEUS between January 2018 and December 2025. Least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic analysis were employed to screen risk factors and establish the MVI prediction model. Three models were developed: a clinical model, an ultrasound model, and a combined model. The performance of the combined model was evaluated and validated using the area under the receiver operating characteristic (AUC), calibration curves, decision curve analysis (DCA), and the Hosmer-Lemeshow test. Results: A total of 261 patients with HCC ≤5 cm were enrolled. Patients were divided into a derivation cohort (n=209) and an external validation cohort (n=52). 85 patients (32.57%) were MVI-positive. LASSO regression and multivariate analysis revealed that AFP, tumor margin, enhanced homogeneity, mosaic, and LI-RADS were significantly associated with MVI. The combined model showed an AUC of 0.880 (95% CI: 0.832-0.929) in the derivation cohort and 0.832 (95% CI: 0.703-0.960) in the external validation cohort. Calibration curves revealed excellent agreement between the model's predicted probability of MVI and the actual observed outcomes. DCA confirmed the excellent net benefits. Conclusion: This model can noninvasive preoperative prediction of MVI risk in patients with HCC ≤5 cm, offering a reliable reference for clinicians in developing personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.